
    
      All cohort participants are assessed annually for at least 5 years, until 6 months after the
      start of renal replacement therapy.

      Each year, data are collected from both medical records and patients interview and
      self-administrated questionnaires are asked to report clinical events.

      Interviews and routine biological measurements are repeated annually.

      CKD-REIN is funded by the Agence Nationale de la Recherche through the 2010
      'Cohortes-Investissements d'Avenir' programme and by the 2010 national Programme Hospitalier
      de Recherche Clinique.

      CKD-REIN is also supported through a public-private partnership with Amgen, Fresenius Medical
      Care, and GlaxoSmithKline since 2012; Baxter and MerckSharp&Dohme-Chibret (France) from 2012
      to 2017; LillyFrance since 2013; Otsuka Pharmaceutical since 2015; Vifor Fresenius since
      2017; AstraZeneca since 2018; and Sanofi-Genzyme from 2012 to 2015.
    
  